查计划对预防高风险艾滋病毒患者癌的影响
Eloïse Leclerc1, Christine Jacomet2, Laurent Siproudhis3
1Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
HIV medicine
|November 30, 2023
概括
这项研究评估了一项针对高风险艾滋病毒患者的全国性门癌症查计划. 虽然没有发现癌症,但该计划并没有显著降低门癌症风险,这凸显了进一步研究的必要性.
科学领域:
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 门癌症是高风险的人类免疫缺陷病毒 (HIV) 患者的一个重大问题.
- 通过查计划的早期检测旨在减少门癌的发病率和死亡率.
- 识别高风险个体和评估查计划的有效性对于患者管理至关重要.
研究的目的:
- 评估全国门癌症查计划对减少艾滋病毒阳性个体癌症风险的影响.
- 评估查计划的遵守与门内皮质瘤 (AIN) 和门癌症发生率之间的关联.
- 为了确定宏观的高度发育不良性病变是否与患癌的风险增加有关.
主要方法:
- 对700名符合法国门癌症查计划 (2011-2020年) 资格的高风险艾滋病毒患者进行了回顾性队列研究.
- 坚持定义为不超过18个月的访问间隔;管理包括可视化,异视镜和活检.
- 统计分析以比较坚持和不坚持的群体之间的癌和AIN风险.
主要成果:
- 诊断出13例部平细胞癌的病例.
- 高度内皮质瘤 (AIN3,AIN2,高度发育不良) 显著增加癌风险.
- 严格遵守 (4.6%) 与不遵守相比,并没有显著降低癌或高度AIN风险.
结论:
- 宏观高度发育不良是门癌的危险因素.
- 目前的查计划没有在预防高风险艾滋病毒人群中的门癌症方面显示出明显的益处.
- 需要进一步的研究,以优化门癌症预防的查策略,在艾滋病毒阳性个体.
相关概念视频
Sexually Transmitted Infections
321
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
321
Retrovirus Life Cycles
46.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.0K
Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356


